Rare diseases healthcare company Swedish Orphan Biovitrum (Sobi) has appointed Norbert Oppitz as its senior vice president for its newly established business area speciality care.
Oppitz has over 30 years’ pharmaceutical and healthcare experience and was most recently a member of the executive committee of BSN Medical in charge of its Latin America business.
In previous capacities, he has led organisations as head of Latin America at Takeda as well as in country management roles at Roche and Aventis Pharma.
He said: “I am excited to join Sobi and I look forward to contributing to the future growth of the company by realising a strategy to build and develop a strong and vital speciality care business unit.”
The new role will see Oppitz work with corporate development and the regional and country organisations.
Guido Oelkers, president and CEO of Sobi, said: “We are delighted that Norbert could join Sobi, he is a true entrepreneur and his experience will be instrumental in realising our ambitions to bring Sobi to the next level as we look for external growth opportunities for our speciality care business.”
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.